Paricalcitol for treatment of secondary hyperparathyroidism in hemodialysis patients with chronic kidney disease: a multicenter case study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034476

Enrollment

Unknown

Registered

2020-07-06

Start date

2020-08-10

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism in hemodialysis patients

Interventions

Paricalcitol:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. Aged >= 18 years; 3. Clinical diagnosis of secondary hyperparathyroidism in hemodialysis patients with chronic kidney disease; 4. Plan to treat secondary hyperparathyroidism with paricalcitol solution; 5. iPTH > 300pg/ml without treatment or iPTH>150pg/ml receiving treatment before enrollment.

Exclusion criteria

Exclusion criteria: 1. Be allergic to vitamin D or similar drugs; 2. Vitamin D intoxication; 3. Patients with drug abuse or addiction; 4. Lactating or pregnant woman or a planned pregnancy within 1 year; 5. Patients with an expected survival of less than 1 year; 6. Other unsuitable conditions for patients to be enrolled.

Design outcomes

Primary

Measure	Time frame
iPTH;size;Dosage of paricalcitol;	—

Secondary

Measure	Time frame
P;ALP;	—

Countries

China

Contacts

Public ContactZuo Li

Peking University People's Hospital

zuolimd@hotmail.com+86 13910028495

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026